000285259 001__ 285259
000285259 005__ 20240229155106.0
000285259 0247_ $$2doi$$a10.1093/brain/awad374
000285259 0247_ $$2pmid$$apmid:37930324
000285259 0247_ $$2ISSN$$a0006-8950
000285259 0247_ $$2ISSN$$a1460-2156
000285259 0247_ $$2altmetric$$aaltmetric:155956565
000285259 037__ $$aDKFZ-2023-02294
000285259 041__ $$aEnglish
000285259 082__ $$a610
000285259 1001_ $$00000-0002-5415-6567$$aGrut, Viktor$$b0
000285259 245__ $$aHuman herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosis.
000285259 260__ $$aOxford$$bOxford Univ. Press$$c2024
000285259 3367_ $$2DRIVER$$aarticle
000285259 3367_ $$2DataCite$$aOutput Types/Journal article
000285259 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1705656888_22128
000285259 3367_ $$2BibTeX$$aARTICLE
000285259 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285259 3367_ $$00$$2EndNote$$aJournal Article
000285259 500__ $$a2024 Jan 4;147(1):177-185
000285259 520__ $$aRecent research indicates that multiple sclerosis is preceded by a prodromal phase with elevated levels of serum neurofilament light chain (sNfL), a marker of axonal injury. The effect of environmental risk factors on the extent of axonal injury during this prodrome is unknown. Human herpesvirus 6A (HHV-6A) is associated with an increased risk of developing multiple sclerosis. The objective of this study was to determine if HHV-6A serostatus is associated with the level of sNfL in the multiple sclerosis prodrome, which would support a causative role of HHV-6A. A nested case-control study was performed by crosslinking multiple sclerosis registries with Swedish biobanks. Individuals with biobank samples collected before the clinical onset of multiple sclerosis were included as cases. Controls without multiple sclerosis were randomly selected, matched for biobank, sex, sampling date and age. Serostatus of HHV-6A and Epstein-Barr virus (EBV) was analysed with a bead-based multiplex assay. The concentration of sNfL was analysed with Single molecule array technology. The association between HHV-6A serology and sNfL was assessed by stratified t-tests and linear regressions, adjusted for EBV serostatus and sampling age. Within-pair ratios of HHV-6A seroreactivity and sNfL were calculated for each case and its matched control. To assess the temporal relationship between HHV-6A antibodies and sNfL, these ratios were plotted against the time to the clinical onset of multiple sclerosis and compared using locally estimated scatterplot smoothing regressions with 95% confidence intervals (CI). Samples from 519 matched case-control pairs were included. In cases, seropositivity of HHV-6A was significantly associated with the level of sNfL (+11%, 95% CI 0.2-24%, P = 0.045), and most pronounced in the younger half of the cases (+24%, 95% CI 6-45%, P = 0.007). No such associations were observed among the controls. Increasing seroreactivity against HHV-6A was detectable before the rise of sNfL (significant within-pair ratios from 13.6 years vs 6.6 years before the clinical onset of multiple sclerosis). In this study, we describe the association between HHV-6A antibodies and the degree of axonal injury in the multiple sclerosis prodrome. The findings indicate that elevated HHV-6A antibodies both precede and are associated with a higher degree of axonal injury, supporting the hypothesis that HHV-6A infection may contribute to multiple sclerosis development in a proportion of cases.
000285259 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000285259 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000285259 650_7 $$2Other$$aEpstein-Barr virus
000285259 650_7 $$2Other$$aaxonal injury
000285259 650_7 $$2Other$$ahuman herpesvirus 6-A
000285259 650_7 $$2Other$$amultiple sclerosis
000285259 650_7 $$2Other$$aneurofilament light chain
000285259 7001_ $$aBiström, Martin$$b1
000285259 7001_ $$aSalzer, Jonatan$$b2
000285259 7001_ $$aStridh, Pernilla$$b3
000285259 7001_ $$00000-0001-8677-1815$$aJons, Daniel$$b4
000285259 7001_ $$aGustafsson, Rasmus$$b5
000285259 7001_ $$aFogdell-Hahn, Anna$$b6
000285259 7001_ $$aHuang, Jesse$$b7
000285259 7001_ $$0P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aButt, Julia Anna$$b8$$udkfz
000285259 7001_ $$aLindam, Anna$$b9
000285259 7001_ $$aAlonso-Magdalena, Lucia$$b10
000285259 7001_ $$aBergström, Tomas$$b11
000285259 7001_ $$00000-0002-0867-4726$$aKockum, Ingrid$$b12
000285259 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b13$$udkfz
000285259 7001_ $$aOlsson, Tomas$$b14
000285259 7001_ $$00000-0003-3930-4354$$aZetterberg, Henrik$$b15
000285259 7001_ $$aBlennow, Kaj$$b16
000285259 7001_ $$aAndersen, Oluf$$b17
000285259 7001_ $$aNilsson, Staffan$$b18
000285259 7001_ $$aSundström, Peter$$b19
000285259 773__ $$0PERI:(DE-600)1474117-9$$a10.1093/brain/awad374$$gp. awad374$$n1$$p177-185$$tBrain$$v147$$x0006-8950$$y2024
000285259 909CO $$ooai:inrepo02.dkfz.de:285259$$pVDB
000285259 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000285259 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000285259 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000285259 9141_ $$y2023
000285259 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000285259 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000285259 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000285259 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-21
000285259 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000285259 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000285259 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000285259 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000285259 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000285259 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000285259 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000285259 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000285259 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN : 2022$$d2023-10-21
000285259 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000285259 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000285259 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bBRAIN : 2022$$d2023-10-21
000285259 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lInfektionen und Krebs-Epidemiologie$$x0
000285259 980__ $$ajournal
000285259 980__ $$aVDB
000285259 980__ $$aI:(DE-He78)F020-20160331
000285259 980__ $$aUNRESTRICTED